{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T11:23:49Z","timestamp":1707737029632},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2007,2,24]],"date-time":"2007-02-24T00:00:00Z","timestamp":1172275200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2007,9,28]]},"DOI":"10.1007\/s10067-007-0590-5","type":"journal-article","created":{"date-parts":[[2007,2,23]],"date-time":"2007-02-23T07:30:29Z","timestamp":1172215829000},"page":"1863-1866","source":"Crossref","is-referenced-by-count":6,"title":["Administration of infliximab in general practitioners\u2019 offices is safe"],"prefix":"10.1007","volume":"26","author":[{"given":"Ulrike","family":"Stuby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Biesenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herwig","family":"Pieringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,2,24]]},"reference":[{"key":"590_CR1","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EH Choy","year":"2001","unstructured":"Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907\u2013916","journal-title":"N Engl J Med"},{"key":"590_CR2","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","volume":"30","author":"DM Knight","year":"1993","unstructured":"Knight DM, Trinh H, Le J et al (1993) Construction and initial characterization of a mouse\u2013human chimeric anti-TNF antibody. Mol Immunol 30:1443\u20131453","journal-title":"Mol Immunol"},{"key":"590_CR3","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594\u20131602","journal-title":"N Engl J Med"},{"key":"590_CR4","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","volume":"366","author":"K Reich","year":"2005","unstructured":"Reich K, Nestle FO, Papp K et al (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366:1367\u20131374","journal-title":"Lancet"},{"key":"590_CR5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"CE Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B et al (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 52:1227\u20131236","journal-title":"Arthritis Rheum"},{"key":"590_CR6","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet 359:1541\u20131549","journal-title":"Lancet"},{"key":"590_CR7","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187\u20131193","journal-title":"Lancet"},{"key":"590_CR8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/0885066604267854","volume":"19","author":"JT Giles","year":"2004","unstructured":"Giles JT, Bathon JM (2004) Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 19:320\u2013334","journal-title":"J Intensive Care Med"},{"key":"590_CR9","first-page":"1018","volume":"33","author":"J Jarand","year":"2006","unstructured":"Jarand J, Zochodne DW, Martin LO et al (2006) Neurological complications of infliximab. J Rheumatol 33:1018\u20131020","journal-title":"J Rheumatol"},{"key":"590_CR10","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0016-5085(99)70294-5","volume":"117","author":"SJ Bickston","year":"1999","unstructured":"Bickston SJ, Lichtenstein GR, Arseneau KO et al (1999) The relationship between infliximab treatment and lymphoma in Crohn\u2019s disease. Gastroenterology 117:1433\u20131437","journal-title":"Gastroenterology"},{"key":"590_CR11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/gut.2005.075937","volume":"55","author":"L Biancone","year":"2006","unstructured":"Biancone L, Orlando A, Kohn A et al (2006) Infliximab and newly diagnosed neoplasia in Crohn\u2019s disease: a multicentre matched pair study. Gut 55:228\u2013233","journal-title":"Gut"},{"key":"590_CR12","first-page":"1307","volume":"33","author":"T Lequerre","year":"2006","unstructured":"Lequerre T, Vittecoq O, Klemmer N et al (2006) Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol 33:1307\u20131314","journal-title":"J Rheumatol"},{"key":"590_CR13","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","volume":"98","author":"A Cheifetz","year":"2003","unstructured":"Cheifetz A, Smedley M, Martin S et al (2003) The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98:1315\u20131324","journal-title":"Am J Gastroenterol"},{"issue":"348","key":"590_CR14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"13","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S et al (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med 13(348):601\u2013608","journal-title":"N Engl J Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-007-0590-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-007-0590-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-007-0590-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:51:06Z","timestamp":1559119866000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-007-0590-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,24]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,9,28]]}},"alternative-id":["590"],"URL":"https:\/\/doi.org\/10.1007\/s10067-007-0590-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,24]]}}}